Tofersen treatment in respiratory onset amyotrophic lateral sclerosis and a variant of uncertain significance in SOD1; a case report
- 28 July 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (10) , 1590-1594
Abstract
No abstract availableKeywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150161810018)
- TRACE
- Takeda Medical Research Foundation
- ZonMw (V0000319)
- Fondation Thierry Latran
- Motor Neurone Disease Association
This publication has 20 references indexed in Scilit:
- Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patientsCommunications Medicine, 2024
- Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patientsJournal of Neurology, 2024
- Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access programeClinicalMedicine, 2024
- A genomic mutational constraint map using variation in 76,156 human genomesNature, 2023
- Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelinesHuman Mutation, 2020
- Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction modelThe Lancet Neurology, 2018
- Amyotrophic lateral sclerosisThe Lancet, 2017
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide TherapyJAMA Neurology, 2013
- Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosisNeuromuscular Disorders, 1996